Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
This trial is active, not recruiting.
|Conditions||recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma|
|Treatments||laboratory biomarker analysis, palbociclib|
|Phase||phase 2/phase 3|
|Sponsor||Southwest Oncology Group|
|Collaborator||National Cancer Institute (NCI)|
|Start date||June 2014|
|End date||June 2017|
|Trial size||42 participants|
|Trial identifier||NCT02785939, NCI-2014-01380, S1400C, U10CA180888|
This phase II trial studies how well palbociclib works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the cyclin dependent kinase 4/6 (CDK4/6) biomarker. CDK4/6 can cause tumor cells to grow more quickly. Palbociclib may decrease the activity of CDK4/6 and may be able to shrink tumors.
|United States||Alaska, California, Colorado, Delaware, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, and 22 other states|
|Other Countries||No locations recruiting|
|Overall Contact||Crystal Miwa, BS|